ライフサイエンスコーパス: opioid receptor

1 sed assay in a cellular system containing mu-opioid receptor.

2 d probes for exploring the role of the kappa-opioid receptor.

3 ivity, and functional activity toward the mu-opioid receptor.

4 that functions as an antagonist of the kappa opioid receptor.

5 argeting truncated splice variants of the mu-opioid receptor.

6 current opioid analgesics that target the mu opioid receptor.

7 equirements of the binding pocket across the opioid receptors.

8 lkaloids at the human mu-, kappa-, and delta-opioid receptors.

9 in regions that contain a high expression of opioid receptors.

10 genetic data suggest the importance of delta-opioid receptors.

11 petitive antagonists at the kappa- and delta-opioid receptors.

12 elying on its partial agonist activity at mu opioid receptors.

13 , structures expressing high levels of kappa opioid receptors.

14 ic-associated subcompartments enriched in mu opioid receptors.

15 which can inhibit dopamine release via kappa-opioid receptors.

16 y for mu (MOR), delta (DOR), and kappa (KOR) opioid receptors across the series, with the diimidazodi

17 ng respiratory pattern, the mechanisms of mu opioid receptor activation in this nucleus were investig

18 To determine whether and how opioid receptor activation induces HAAF in humans, 12 he

19 s in humans demonstrating that pharmacologic opioid receptor activation induces some of the clinical

20 echanisms that modulate calcium channels via opioid receptor activation is fundamental to our underst

21 hydroxylase (TH) promoter, we found that mu opioid receptor activation led to a decrease in inhibito

22 Here the authors show that opioid receptor activation recruits peroxiredoxin 6 (PRD

23 igand recognition features important for pan opioid receptor activity, using chemical modifications o

24 mily, including rhodopsin (visual receptor), opioid receptors, adrenergic receptors, adenosine recept

25 single-digit nanomolar to subnanomolar kappa-opioid receptor affinity, full kappa agonistic activity

26 alpha-helix associated with decreased kappa-opioid receptor affinity.

27 with a mechanism of action that includes mu opioid receptor agonism/delta opioid receptor antagonism

28 A high-internalizing delta opioid receptor agonist (SNC80) preferentially recruited

29 Intrathecal injection of the mu-opioid receptor agonist [D-Ala(2), NMe-Phe(4), Gly-ol(5)

30 ent with mixed opioid effects (mu- and kappa-opioid receptor agonist and delta-opioid receptor antago

31 vation through both pathways, whereas the mu opioid receptor agonist DAMGO decreased D2-receptor acti

32 ining addicted pregnant women on long-acting opioid receptor agonist is the most common strategy to m

33 Bath application of the kappa opioid receptor agonist U69593 decreased D2-receptor act

34 sion of phasic dopamine release by the kappa-opioid receptor agonist, salvinorin A, supporting a sele

35 ity on the A-ring in its activity as a kappa-opioid receptor agonist.

36 aversion induced by thermal pain or a kappa opioid receptor agonist.

37 ous natural compound known to function as an opioid-receptor agonist, and is undergoing clinical tria

38 Here, we demonstrate that delta opioid receptor agonists differentially recruit arrestin

39 Mu-opioid receptor agonists represent mainstays of pain man

40 In Caenorhabditis elegans, opioid receptor agonists suppress the overall withdrawal

41 In Caenorhabditis elegans, opioid receptor agonists, such as morphine, mimic seroto

42 gynine, are partial agonists of the human mu-opioid receptor and competitive antagonists at the kappa

43 itro, the hybrids behaved as agonists at the opioid receptors and antagonists at the nociceptin recep

44 by the activation of mu-, delta-, and kappa-opioid receptors and by adrenergic alpha2A receptors in

45 ade tracer from rVLM were co-labeled with mu-opioid receptors and juxtaposed to endorphinergic fibers

46 oncomitant opioid release could downregulate opioid receptors and promote the development of obesity.

47 Given the dense expression of mu opioid receptors and the role of dopamine in pain, the r

48 lation of the vPAG/DR dopamine neurons by mu opioid receptors and to (2) dissect the anatomy and neur

49 rescued by the expression of the human kappa opioid receptor, and injection of human opioid receptor

50 asal forebrain cholinergic neurons via kappa-opioid receptors, and decreases afferent excitatory syna

51 inhibition, in pain perception pathways via opioid receptors, and is also involved in alcoholism.

52 f which cause toxicity via interactions with opioid receptors, and result in a multifunctional bioche

53 hormones (estrogen and progesterone), delta-opioid receptors, and T cells of the adaptive immune sys

54 h G protein-coupled receptors, in particular opioid receptors, and their downstream effectors PKA/CRE

55 at includes mu opioid receptor agonism/delta opioid receptor antagonism.

56 , (+)-naloxone, the non-opioid isomer of the opioid receptor antagonist (-)-naloxone, in infection-as

57 show further that a selective and potent mu-opioid receptor antagonist (GSK1521498) reduced both alc

58 latory effects of OPRM1 genetic variation on opioid receptor antagonist attenuation of alcohol- and f

59 ABAA agonist muscimol into the IC and the mu-opioid receptor antagonist CTAP into the contralateral N

60 or-1 antagonist antalarmin but not the kappa opioid receptor antagonist JDTic.

61 to spinal naloxone and to the selective mu1-opioid receptor antagonist naloxonazine.

62 stemic or hypothalamic administration of the opioid receptor antagonist naloxone blocks acute CB1R-in

63 VT administration of OrxA+/-DynA+/-the kappa-opioid receptor antagonist nor-binaltorphimine (NorBNI)

64 A mu opioid receptor antagonist restored GABA currents in D2-

65 his SNP on alcohol-related behaviors, and on opioid receptor antagonist treatments, have been inconsi

66 and kappa-opioid receptor agonist and delta-opioid receptor antagonist), in patients with IBS with d

67 al pretreatment with naloxone, non-selective opioid receptor antagonist, did not affect the effect of

68 ety of naldemedine, a peripherally acting mu-opioid receptor antagonist, for the treatment of opioid-

69 Microinjection of ICI 174,864, a delta-opioid receptor antagonist, into the rVLM of EA-treated

70 onthly injectable formulation of the full mu-opioid receptor antagonist, is effective for the prevent

71 Nalmefene is a micro and delta opioid receptor antagonist, kappa opioid receptor partia

72 OT coadministered with a mu-opioid receptor antagonist, naloxone, invoked a supralin

73 trexone and GSK1521498, a novel selective mu-opioid receptor antagonist, on both voluntary alcohol-in

74 en A118G variation and the effects of two mu-opioid receptor antagonists in a clinical lab setting.

75 l-4-(3-hydroxyphenyl)piperidine (1) class of opioid receptor antagonists, procedures were developed f

76 lpiperazines 4 and 5 were reported to be pan opioid receptor antagonists, while 6 was a MOR agonist.

77 s and their use in preparing potential kappa opioid receptor antagonists.

78 ht have implications for the clinical use of opioid receptor antagonists.

79 phai-G-protein-coupled receptor inactivation.Opioid receptors are important modulators of nociceptive

80 imaging in HEK293 cells revealed that delta opioid receptors are in pre-engaged complexes with arres

81 both expression levels and the proportion of opioid receptors are strongly lateralized in the spinal

82 elop a new Gi-coupled DREADD using the kappa-opioid receptor as a template (KORD) that is activated b

83 n of spinal opioid receptors, putatively mu1-opioid receptors, as indicated by its sensitivity to spi

84 3 is in pre-engaged complexes with the delta opioid receptor at the cell membrane and low-internalizi

85 Activation of both melanocortin and mu-opioid receptors at the DMV inhibits Sst-GABA DMV neuron

86 g associations between baseline IL-18 and mu-opioid receptor availability in major depressive disorde

87 , showed an overall reduction of baseline mu-opioid receptor availability in regions implicated in pa

88 were negatively correlated with baseline mu-opioid receptor availability in the aINS and subgenual a

89 G, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic d

90 restrict expression of the inhibitory kappa opioid-receptor based DREADD (KORD) in vSub-->NAc shell

91 on were reduced by EA and then restored with opioid receptor blockade in the PVN.

92 Cortisol response following mu-opioid receptor blockade using naltrexone in 119 of thes

93 in D2/D3R BPND were also correlated with mu-opioid receptor BPND and pain-induced endogenous opioid

94 gonists in [(35)S]GTPgammaS assays at the mu opioid receptor but failed to recruit beta-arrestin-2, w

95 cell lines affected endocytosis of the delta-opioid receptor, but not the beta2-adrenergic receptor,

96 ts MCPO/SI cholinergic neurons through kappa-opioid receptors by (1) activation of a G protein-couple

97 Furthermore, we examined delta opioid receptor-Ca(2+)channel coupling in dorsal root ga

98 peroxiredoxin 6 (PRDX6) is recruited to the opioid receptor complex by c-Jun N-terminal kinase (JNK)

99 With the availability of the opioid receptor crystal structures, our SAR analysis of

100 is a structurally distinct PAM for the delta-opioid receptor (delta-OR) that has been reported to exh

101 The delta opioid receptor (deltaR) is a promising alternate target

102 Although the delta opioid receptor (deltaR) is an attractive option, a crit

103 t controls the surface delivery of the delta opioid receptor (deltaR).

104 Opioid receptor density in the frontal cortex predicted

105 exclusively through MOPs, or involves delta opioid receptors (DOPs).

106 found increased G protein coupling for delta opioid receptor (DOR) and mu opioid, but not other Gi/o

107 receptors (KORs) and some affinity at delta opioid receptor (DOR) and opioid receptor-like 1 (ORL-1)

108 es of mu-opioid receptor (MOR) agonist/delta-opioid receptor (DOR) antagonist ligands increases DOR a

109 The delta opioid receptor (DOR) is broadly expressed throughout th

110 Activation of the delta-opioid receptor (DOR) produces similar analgesia with re

111 inhibit glutamate release through the delta-opioid receptor (DOR), an effect potentiated by a DOR-po

112 OD), acting as a selective agonist at the mu-opioid receptor encoded by the gene OPRM1.

113 depends heavily on opioids acting through mu opioid receptors encoded by the Oprm1 gene, which underg

114 conserved allosteric binding site across the opioid receptor family that can accommodate structurally

115 The NOP receptor, the fourth member of the opioid receptor family, is involved in pain, drug abuse,

116 , the most recently identified member of the opioid receptor family.

117 ucleotide polymorphism (SNP) in the human mu-opioid receptor gene (OPRM1 A118G) has been widely studi

118 whether the sole targeted deletion of the mu opioid receptor gene (Oprm1) alters the brain connectome

119 ymorphism (rs1799971, Asn40Asp) of the micro-opioid receptor gene (OPRM1) is associated with the risk

120 oholism are moderated by variation at the mu-opioid receptor gene locus (OPRM1).

121 Extensive 3' alternative splicing of the mu opioid receptor gene OPRM1 creates multiple C-terminal s

122 otide polymorphism (SNP rs1799971) in the mu-opioid receptor gene, OPRM1, has been much studied in re

123 ed the colocalization of mu-opioid and kappa-opioid receptor genes and OT genes at the OT-releasing s

124 rs of G protein-coupled receptors, including opioid receptors, have been proposed as possible therape

125 of different arrestin isoforms to the delta opioid receptor in mice.

126 by the expression of npr-17 or a human kappa opioid receptor in the two ASI sensory neurons, with ASI

127 First, Dbx1 preBotC neurons express kappa-opioid receptors in addition to mu-opioid receptors that

128 lar markers, as well as coexpression with mu-opioid receptors in DRG and brain regions.

129 Though the role of opioid receptors in long-term depression in striatum has

130 The activation of opioid receptors in peripheral inflamed tissue can reduc

131 ing of the neuropeptide beta-endorphin to mu-opioid receptors in the central nervous system (CNS) is

132 Opioid receptors in the central nervous system are impor

133 naloxone, suggesting the participation of mu-opioid receptors in the reinforcing properties of sufent

134 rance during pregnancy due to an increase in opioid receptors in the spinal cord.

135 te analgesic tolerance to morphine and kappa opioid receptor inactivation in vivo.

136 tion of NF1 in striatal neurons prevents the opioid-receptor-induced activation of Ras and eliminates

137 or sufentanil when given the preferential mu-opioid receptor inverse agonist naloxone, suggesting the

138 systemic side effects, targeting peripheral opioid receptors is an attractive alternative treatment

139 rthermore, we show that the activation of mu-opioid receptors is not due to the release of endogenous

140 Acute desensitization of mu opioid receptors is thought to be an initial step in the

141 or insula with a downregulation of the kappa opioid receptor (Kappa), as well as decreased DNA methyl

142 effective PAM at the mu-OR and at the kappa-opioid receptor (kappa-OR), but it is ineffective at the

143 Mice lacking the kappa opioid receptor (kappaOR) and adenoviral vectors overexp

144 Among the opioid receptors, the kappa-opioid receptor (kappaOR) has been gaining considerable

145 tressful experiences potently activate kappa opioid receptors (kappaORs).

146 The kappa-opioid receptor (KOP-r) system and its endogenous ligand

147 promoted phosphorylation of the mouse kappa opioid receptor (KOPR) at residues S356, T357, T363, and

148 TEMENT Emerging evidence suggests that kappa opioid receptor (KOR) activation can selectively modulat

149 design of highly potent and selective kappa-opioid receptor (KOR) agonists (conorphins) with excepti

150 Kappa opioid receptor (KOR) agonists have the potential to be

151 Administration of the kappa-opioid receptor (KOR) antagonist JDTic (30 mg/kg, i.p.)

152 Administration of a kappa-opioid receptor (KOR) antagonist reduced stress effects

153 We have studied changes in kappa opioid receptor (KOR) binding availability in vivo with

154 peptide (dynorphin) bound to the human kappa opioid receptor (KOR) has been determined by liquid-stat

155 The kappa-opioid receptor (KOR) has been implicated in depression,

156 The kappa-opioid receptor (KOR) has emerged as a promising target

157 Endogenous dynorphin signaling via the kappa-opioid receptor (KOR) in the nucleus accumbens (NAcc) po

158 like peptide expression and heightened kappa-opioid receptor (KOR) signaling in the central nucleus o

159 Previously it was demonstrated that kappa-opioid receptor (KOR) signaling in the striatum plays a

160 increased spinal dynorphin release and kappa-opioid receptor (KOR) signaling, as well as the emergenc

161 Given that the kappa opioid receptor (KOR) system has been implicated in psyc

162 The dynorphin (DYN)/kappa-opioid receptor (KOR) system has been implicated in stre

163 The dynorphin/kappa-opioid receptor (KOR) system has been previously implica

164 The dynorphin (DYN)/kappa-opioid receptor (KOR) system plays a conserved role in s

165 ioid receptors with preference for the kappa opioid receptor (KOR), and its structure-activity relati

166 (5),Dap(8))]dynorphin A(1-11)NH2) is a kappa opioid receptor (KOR)-selective antagonist in vitro, is

167 ide dynorphin, an endogenous ligand at kappa opioid receptors (KOR) that suppresses dopamine release

168 l inhibitory DREADD in which a mutated kappa-opioid receptor (KORD) is activated by the pharmacologic

169 mogenetic tool based on the inhibitory kappa opioid receptor (KORD) that can be used in conjunction w

170 nity for mu opioid receptor (MORs) and kappa opioid receptors (KORs) and some affinity at delta opioi

171 iated through downstream activation of kappa-opioid receptors (KORs) and that activation of these rec

172 kappa-Opioid receptors (KORs) and their endogenous ligand dyno

173 Kappa opioid receptors (KORs) are highly enriched within the v

174 Kappa opioid receptors (KORs) have an important role in regula

175 Kappa opioid receptors (KORs) have been implicated in anxiety

176 e dynorphin, which acts at presynaptic kappa-opioid receptors (KORs) on dopaminergic afferents and ca

177 se in arachidonic acid levels through the mu-opioid receptors leads to the sole activation of microgl

178 were introduced into the endogenous peptide opioid receptor ligand Leu-enkephalin as a model compoun

179 To optimize the structure of a mu-opioid receptor ligand, analogs H-Tyr-c[D-Lys-Xxx-Tyr-Gl

180 appa opioid receptor, and injection of human opioid receptor ligands mimics exogenous opiates, highli

181 represent the first example of mirror image opioid receptor ligands with both optical antipodes havi

182 To obtain selective and potent opioid receptor ligands, we synthesized dehydro derivati

183 s and side effects; endogenous and exogenous opioid receptor ligands; and conventional and novel opio

184 esis of the gem-difluoro group present in an opioid receptor-like 1 (ORL-1) antagonist that is curren

185 affinity at delta opioid receptor (DOR) and opioid receptor-like 1 (ORL-1) receptors.

186 Inactivation of opioid receptors limits the therapeutic efficacy of morp

187 effect of buprenorphine on CCL2 signaling is opioid receptor mediated.

188 dministration of 14 produced dose-dependent, opioid-receptor mediated antinociception in the mouse, a

189 Therefore, this remission represents an opioid receptor-mediated suppression of a sustained hype

190 ositive allosteric modulator (PAM) of the mu-opioid receptor (micro-OR).

191 ls coexpressing TRPC4 and Gi/o-coupled micro opioid receptor, micro agonist elicited currents biphasi

192 micro-Opioid receptors (microORs) are G-protein-coupled recept

193 Opioids, agonists of micro-opioid receptors (microORs), are the strongest pain kill

194 Functional selectivity at the micro opioid receptor (microR), a prototypical G-protein-coupl

195 We further assessed how opioid receptors modulate these two mechanisms of releas

196 member mitragynine, are an unusual class of opioid receptor modulators with distinct pharmacological

197 e tyrosine kinase, c-Src, participates in mu opioid receptor (MOP) mediated inhibition in sensory neu

198 The mu-opioid receptor (MOPr) is a clinically important G prote

199 residues in the C-terminal tail of the micro-opioid receptor (MOPr) is thought to be a key step in de

200 In the case of the mu-opioid receptor (MOPr), this desensitization may play a

201 Mu-opioid receptors (MOPRs) are critically involved in the

202 Mu-opioid receptors (MOPRs) are the target of heroin and ot

203 ids analgesics is mainly attributed to micro-opioid receptor (MOR) activation leading to G protein si

204 orphinan skeleton plays a key role in the mu-opioid receptor (MOR) activity in vitro and in vivo.

205 kurkinorin (5), is a potent and selective mu-opioid receptor (MOR) agonist (EC50 = 1.2 nM, >8000 mu/k

206 Head-to-tail cyclization of the mu opioid receptor (MOR) agonist [Dmt(1)]DALDA (H-Dmt-d-Arg

207 ed intradermal injection of the selective mu-opioid receptor (MOR) agonist DAMGO induced mechanical h

208 ahydroquinoline (THQ) core of a series of mu-opioid receptor (MOR) agonist/delta-opioid receptor (DOR

209 mu-Opioid receptor (MOR) agonists are often used to treat s

210 there was no difference in the ability of mu-opioid receptor (MOR) agonists to inhibit sIPSCs in POMC

211 We examined whether high affinity mu opioid receptor (MOR) agonists, endomorphin-1 (E-1) and

212 effects of the systemic administration of mu-opioid receptor (MOR) agonists.

213 on specific to PDAC is identified between mu opioid receptor (MOR) and somatostatin receptor 2 (SSTR2

214 ized in substance dependence, with higher mu-opioid receptor (MOR) availability reported in alcohol,

215 t induced by inhibition of the endogenous mu-opioid receptor (MOR) by naltrexone, MOR knockout, and G

216 adverse effects through activation of the mu opioid receptor (MOR) encoded by the Oprm1 gene.

217 report convergent evidence for decreased mu-opioid receptor (MOR) function in the female rat LC.

218 Since the discovery of mu-opioid receptor (MOR) gene two decades ago, various regu

219 the function of class A GPCRs such as the mu-opioid receptor (MOR) is still unclear, insight as to ho

220 IFICANCE STATEMENT Desensitization of the mu-opioid receptor (MOR) is thought to underlie the develop

221 In mu-opioid receptor (MOR) knock-out (KO) mice, responses did

222 in 2 [EM2; the highly specific endogenous mu-opioid receptor (MOR) ligand] induces antinociception th

223 The mu-opioid receptor (MOR) localized in the ventral tegmental

224 SIGNIFICANCE STATEMENT: The mu-opioid receptor (MOR) localized in the ventral tegmental

225 The known mu-opioid receptor (MOR) partial agonist, buprenorphine, wa

226 eptor subtypes, we reveal that endogenous mu-opioid receptor (MOR) signaling strongly drives sodium a

227 G polymorphism is the most widely studied mu-opioid receptor (MOR) variant.

228 ivate a potassium conductance through the mu-opioid receptor (MOR), suggesting for the first time tha

229 Splice variants of the mu opioid receptor (MOR), which mediates opioid actions, ha

230 eceptors, including dopamine receptor and mu opioid receptor (MOR).

231 that tianeptine is a full agonist at the mu opioid receptor (MOR).

232 ic and analgesic effects by acting on the mu-opioid receptor (MOR).

233 target for clinically used opioids is the mu-opioid receptor (MOR).

234 focused on the signaling cascades of the mu-opioid receptor (MOR).

235 lasticity by regulating activation of the mu-opioid receptor (MOR).D1LR stimulation with agonist SKF

236 The mu-opioid receptor (MOR, encoded by Oprm1) agonists are the

237 at dopamine D1-like receptors (D1LRs) and mu-opioid receptors (MOR) in the spinal dorsal horn constit

238 f acute physical exercise on the cerebral mu-opioid receptors (MOR) of 22 healthy recreationally acti

239 gands with agonist bioactivities at mu/delta opioid receptors (MOR/DOR) and antagonist bioactivity at

240 scribe structural features of a series of mu-opioid-receptor (MOR)-selective agonists that preferenti

241 We used PET and the mu-opioid-receptor (MOR)-specific ligand [(11)C]carfentanil

242 In addition to binding to the neuronal mu-opioid receptor, morphine binds to the innate immune rec

243 hine (BPN), a drug with high affinity for mu opioid receptor (MORs) and kappa opioid receptors (KORs)

244 Mu opioid receptors (MORs) are central to pain control, dru

245 e provide evidence that the activation of mu-opioid receptors (MORs) by the specific agonist DAMGO ([

246 We found that mu opioid receptors (MORs) expressed by primary afferent no

247 Activation of somatic mu-opioid receptors (MORs) in hypothalamic proopiomelanocor

248 Neurobiologically, Mu opioid receptor mRNA expression was lower in striatal 'h

249 crued to suggest that excessive intra-PFC mu-opioid receptor (mu-OR) signaling alters the PFC respons

250 Activation of the mu-opioid receptor (muOR) is responsible for the efficacy o

251 depression-are thought to be mediated by mu-opioid-receptor (muOR) signalling through the beta-arres

252 esics, such as morphine, which target the mu opioid receptor (muR), have been the mainstay of pain ma

253 ecades since the discovery of the nociceptin opioid receptor (NOP) and its ligand, nociceptin/orphani

254 ased signaling at the nociceptin/orphanin FQ opioid receptor (NOPR), the most recently identified mem

255 nversely, pharmacological activation of rACC opioid receptors of injured, but not pain-free, animals

256 The presence of functional opioid receptors on epidermal keratinocytes, with attend

257 esults from iLTD through activation of delta-opioid receptors on parvalbumin-expressing interneurons.

258 ing mice with genetic deletion of individual opioid receptors or after pharmacological blockade of re

259 tial evidence in support of the formation of opioid receptor (OR) di-/oligomers suggests previously u

260 inhibited by activation of G protein-coupled opioid receptors (ORs).

261 and delta opioid receptor antagonist, kappa opioid receptor partial agonist that has recently been a

262 nderstanding the pharmacology of this fourth opioid receptor/peptide system, aided by genetic and pha

263 his depression required activation of spinal opioid receptors, putatively mu1-opioid receptors, as in

264 ular mechanisms of protection, such as delta-opioid receptor regulation and mitophagy, reinforce the

265 lpha2A adrenergic and mu-, delta-, and kappa-opioid receptors reinstated hyperalgesia during remissio

266 Antagonists of alpha2A-adrenergic and delta-opioid receptors reinstated hyperalgesia in WT mice and

267 The activation of central mu-opioid receptors related to CXCL1-CXCR2 signaling plays

268 cation of recording sites with respect to mu-opioid receptor-rich striosomes.

269 Opioid receptor screening of a conopeptide library led t

270 ed to attenuate the central projection of mu-opioid receptor-sensitive locomotor muscle afferents dur

271 h the ebb and flow of spinal dynorphin/kappa-opioid receptor signaling over the estrous cycle, as wel

272 d the impact of modulating both mu and kappa opioid receptor signaling using the mixed agonist/antago

273 ereas a role for kappa (KOR) and delta (DOR) opioid receptor signaling was not detected, at least in

274 ine with previous studies suggesting that mu-opioid receptor signalling has been elaborated beyond it

275 We scanned volunteers using the mu-opioid receptor-specific radioligand [(11)C]carfentanil

276 The mRNA levels for the various mu opioid receptor splice variants were assessed to determi

277 sal root ganglion neurons, independent of mu opioid receptor stimulation or G protein activation.

278 es by dose dependently acting on distinct mu-opioid receptor subtypes located at different levels of

279 petite, the endogenous influence of specific opioid receptor subtypes within distinct brain regions r

280 opioid ligands binding to the three classic opioid receptor subtypes, mu, kappa and delta, have high

281 ing selective pharmacological antagonists of opioid receptor subtypes, we reveal that endogenous mu-o

282 Pathophysiology within the opioid receptor system is increasingly recognized in sub

283 suggesting it acts through an alternative mu-opioid receptor target.

284 yna alkaloids adopt a binding pose at the mu-opioid receptor that is distinct from that of classical

285 ess kappa-opioid receptors in addition to mu-opioid receptors that heretofore have been associated wi

286 l (50 mM) to striatal slices activates delta opioid receptors that reside on FSI axon terminals and n

287 and delta, have high affinity at the fourth opioid receptor, the nociceptin/orphanin FQ receptor (NO

288 Among the opioid receptors, the kappa-opioid receptor (kappaOR) ha

289 s the structure, function, and plasticity of opioid receptors; the central and peripheral sites of an

290 o acids do not bind to either cannabinoid or opioid receptors, thus reducing adverse actions and maki

291 venous PG-M exclusively activated peripheral opioid receptors to produce analgesia in inflamed rat pa

292 Dyn A acts on opioid receptors to reduce pain in the spinal cord, but

293 Using mouse and human recombinant kappa opioid receptors transfected into a host cell, two selec

294 to a similar region on all three traditional opioid receptor types (micro-OR, delta-OR, and kappa-OR)

295 increased enkephalin tone on presynaptic mu opioid receptors was responsible for occluding the LTD.

296 Likewise, when tagged micro-opioid receptors were expressed in dopamine neurons they

297 Therefore, these studies examined which opioid receptors were involved in BPN's effects on anima

298 nine are G-protein-biased agonists of the mu-opioid receptor, which do not recruit beta-arrestin foll

299 is is consistent with nalmefene's actions on opioid receptors, which modulate the mesolimbic dopamine

300 in A (Dyn A) is an endogenous ligand for the opioid receptors with preference for the kappa opioid re